• 대한의생명과학회지
• /
• 제11권4호
• /
• pp.555-559
• /
• 2005

Evaluate the triolein emulsion could disrupt the barriers and to suggest as an experimental model in blood-ocular barrier studies. Triolein emulsion was infused into the carotid artery in the experimental group ten cats. Normal saline was used in another the control group ten cats. Pre contrast and postcontrast T1-weighted MR images were obtained at 30 minutes and 3 hours after embolization. Signal intensities were evaluated in the anterior, posterior chamber and in the vitreus qualitatively and quantitatively. Postembolization 30 minutes MR images were not different from those of the control group. Postembolization 3 hour MR images demonstrated delayed contrast enhancement in the anterior chamber of the ipsilateral and contralateral eyeballs and in the posterior chamber of the ipsilateral eyeball. Delayed contrast enhancement of the posterior chamber of the ipsilateral eyeball was statistically significant (P<0.05). The present study demonstrated significant contrast enhancement in the posterior chamber with infusion of triolein emulsion and can be a model in blood-aqueous barrier studies.

• 대한수의사회지
• /
• 제47권1호
• /
• pp.42-46
• /
• 2011

임상에 있어 눈에 적용하는 약물의 적용은 정상적인 조직을 손상시키지 않으면서 원하는 안구 조직에 목표로 하는 용량의 안약을 전달하는 것이 목적이라고 할 수 있다. 그러나 이러한 간단한 목적도 실제로 환자의 성격, 안구 조직의 민감성, 그리고 친지질성 각막 외피세포(lipophilic corneal epithelium), 친수성 각막 그리고 공막의 간질층(hydrophilic corneal and sclera stroma), 결막의 임파 조직, 맥락막의 혈관 등, Blood-ocular barrier등 안구의 조직 자체의 장벽들로 인해 어려움을 내포하고 있는 것 역시 사실이다. 평소에 처방하고 있는 안약들을 조금 더 효과적으로 전달하기 위해 필요한 눈에 대한 이해에 대해 다루어 보도록 한다.

• Journal of Korean Neurosurgical Society
• /
• 제30권5호
• /
• pp.638-641
• /
• 2001

Carboplatin intra-arterial chemotherapy(IAC) has an advantage of increased uptake during the first passage of the drugs through tumor capillaries. Although not common, this type of therapy is known to cause neurological complications, myelosuppression, and ototoxicity. However, the incidence of ocular toxicity is reported to be rare. Eleven of our patients with glioma(Grade II Astrocytoma : 3, Grade III Astrocytoma : 1, Grade IV Astrocytoma : 5, Gliofibroma : 1, Oligodendroglioma : 1) underwent IAC regimen with carboplatin($300mg/m^2$) which were administrated after blood-brain barrier disruption. Of there, 3 patients had ocular complications after supra-ophthalmic IAC injection of carboplatin but fully recovered following steroid therapy. Although our results from IAC seem to be favorable for these patients, we suggest that its complications, such as ocular toxicity, need to be carefully considered prior to treatment.